Trials / Withdrawn
WithdrawnNCT05550363
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)
A Phase 3, Prospective, Randomized, Double-masked, Placebo-controlled, Parallel-design, Multicenter Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- EyePoint Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 3, Prospective, Randomized, Double-masked, Placebo-controlled, Parallel-design, Multicenter Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated with Cataract Surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexycu | 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg |
| OTHER | Placebo/Vehicle | Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2023-09-01
- Completion
- 2023-09-01
- First posted
- 2022-09-22
- Last updated
- 2024-04-03
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05550363. Inclusion in this directory is not an endorsement.